Visão geral da empresa
Illumina, Inc. operates as a premier provider of sequencing- and array-based solutions designed for genetic and genomic analysis across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The corporation focuses on delivering essential instruments and consumables, including reagents, flow cells, and other critical components required for advanced genomic research and diagnostic applications. This entity functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which encompasses the development and commercialization of medical testing technologies. The company demonstrates substantial scale with a market capitalization of $19.57B and annual revenue reaching $4.34B, supported by a workforce of 8600 employees. These valuation and revenue figures indicate that Illumina maintains a significant position within the global healthcare technology landscape, reflecting strong market confidence and a large operational footprint that enables broad geographic reach.
Saúde financeira
The company reports a trailing twelve-month revenue of $4.34B, generating net income of $850.00M and an EBITDA of $1.14B during the same period. The gap between the total revenue and net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, amount to approximately $3.49B before interest and taxes. Free cash flow stands at $786.00M, which signifies a robust capacity to generate liquidity after capital expenditures, thereby providing the company with considerable financial flexibility for research and development or debt repayment. The gross margin is reported at 68.2%, indicating high pricing power and efficient production costs relative to the price of sequencing instruments. The operating margin of 19.7% and profit margin of 19.6% suggest that the company effectively manages its overhead and converts a significant portion of sales into bottom-line earnings. Total cash holdings of $1.63B are lower than the total debt of $2.55B, resulting in a debt-to-equity ratio of 93.76, which characterizes a leveraged balance sheet where liabilities exceed equity. Despite the leverage, the current ratio of 2.08 indicates strong short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet obligations as they fall due. Return on Equity is 33.4% and Return on Assets is 8.4%, metrics that reveal management is highly effective at utilizing shareholder equity to generate profits while maintaining a moderate efficiency in utilizing the total asset base.
Avaliação de valorização
The trailing twelve-month P/E ratio is 23.49, while the forward P/E is 21.96, implying that the market expects earnings growth that will justify a lower multiple in the future compared to historical performance. The price-to-book ratio stands at 7.19, indicating that the market values the company at a significant premium over its net book value, likely reflecting the intangible assets and growth potential inherent in genomic technology. The price-to-sales ratio is 4.51, and the EV/EBITDA multiple is 17.99, suggesting that investors are willing to pay a high multiple for revenue and earnings, consistent with high-growth healthcare sectors. The stock has traded between a 52-week low of $68.70 and a 52-week high of $155.53, providing a clear range for volatility analysis. The beta value of 1.49 indicates that the stock price is 49% more volatile than the broader market, meaning it tends to amplify market movements with higher swings in both directions.
Growth & Income
Revenue growth for the trailing twelve months is 5.0%, whereas earnings growth is significantly higher at 86.4%, implying that earnings are expanding at a much faster rate than sales, likely driven by margin expansion or share buybacks rather than top-line volume increases. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status indicates that the company retains all its earnings to reinvest into growth initiatives, such as new sequencing technologies or global expansion, rather than distributing cash to shareholders. Consequently, the overall growth and income profile is defined by aggressive capital reinvestment and substantial earnings acceleration rather than income generation through dividends, aligning with the typical lifecycle of a high-growth technology firm in the diagnostics sector.